Product Information
TIOTROPIUM 18 MCG CAP-INHALER is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $11.8109 per EA under NDC 68180096412. Its NADAC has been published 155 times since Oct 18, 2023.
FDA first approved this application on Jun 20, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
18 ug/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180096412
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL; RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
TIOTROPIUM BROMIDE MONOHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA211287FDA Approved
6/20/2023
TE Code
AB
On Market Since
8/16/2023
Pharmacological Classes
Price Statistics
The NADAC for TIOTROPIUM 18 MCG CAP-INHALER has been published 155 times since Oct 18, 2023, and over the history we have for it it has declined 14.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.8109 per EA |
|---|---|
| All-time high | $13.9717 (Jan 10, 2024) |
| All-time low | $11.2708 (Jul 17, 2024) |
| 52-week high | $12.4871 |
| 52-week low | $11.4807 |
| Median price | $12.3469 |
| Average price | $12.4593 |
| Largest weekly change | +17.7% (Jun 19, 2024) |
| Weeks tracked | 155 |
| Tracking since | Oct 18, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Tiotropium Bromide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tiotropium Bromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TIOTROPIUM 18 MCG CAP-INHALER?
The current National Average Drug Acquisition Cost (NADAC) for TIOTROPIUM 18 MCG CAP-INHALER, manufactured by Lupin Pharmaceuticals Inc., is $11.8109 per EA (NDC 68180096412), effective Sep 30, 2026.
How has the price of TIOTROPIUM 18 MCG CAP-INHALER changed over time?
Over the history we have for it, the NADAC for TIOTROPIUM 18 MCG CAP-INHALER has declined 14.9%. It has been tracked across 155 weekly CMS publications since Oct 18, 2023.
What are the highest and lowest recorded NADAC prices for TIOTROPIUM 18 MCG CAP-INHALER?
Since Oct 18, 2023, the NADAC for TIOTROPIUM 18 MCG CAP-INHALER has ranged from a low of $11.2708 (Jul 17, 2024) to a high of $13.9717 (Jan 10, 2024), with a median of $12.3469 per EA.
Are there cheaper alternatives to TIOTROPIUM 18 MCG CAP-INHALER?
No other NADAC-published product currently shares the active ingredient and strength of TIOTROPIUM 18 MCG CAP-INHALER in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TIOTROPIUM 18 MCG CAP-INHALER?
TIOTROPIUM 18 MCG CAP-INHALER (NDC 68180096412) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.